Hip fractures in older people are a major global health problem that causes a lot of sickness, mortality and high healthcare costs. Blood transfusions are often necessary because of the way the fracture is, how much blood is lost during surgery and the fact that the person has anaemia.However, transfusion carries risks including transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), infection, and immunomodulation. The debate between liberal and restrictive transfusion thresholds has intensified over the last two decades, with multiple randomised controlled trials (RCTs) and meta-analyses providing insights. Yet, anatomical factors, variations in practice, and the patient-centred outcomes demand further clarity. This review thus integrates anatomical and clinical perspectives.
This narrative review followed the SANRA (Scale for the Assessment of Narrative Review Articles) framework.
Search Strategy
A structured search of PubMed, Scopus, and Google Scholar was conducted for studies published between January 2000 and July 2024. Keywords included “hip fracture,” “geriatric,” “blood transfusion,” “transfusion thresholds,” “tranexamic acid,” “iron therapy,” “patient blood management,” “hidden blood loss,” and “orthopaedic surgery.” Boolean operators were applied, and reference lists of included articles were manually screened.
Inclusion Criteria
RCTs, cohort studies, and case–control studies.
Systematic reviews, meta-analyses, and guideline statements.
Articles on anatomical factors, transfusion thresholds, or PBM in hip fracture surgery.
Exclusion Criteria
Case reports, conference abstracts, and expert opinions.
Non-English studies.
Articles unrelated to hip fracture or transfusion practices.
Selection and Synthesis
Two authors independently screened titles and abstracts; disagreements were resolved by a third and fourth author. Data were organised under six domains:
Anatomical basis of blood loss
Evolution of transfusion thresholds
Transfusion practices
Blood conservation strategies and PBM
Clinical outcomes linked to transfusion
Limitations of current evidence
Findings are presented narratively and in tabular summaries. All references were verified using PubMed and DOI registries.
Anatomical Basis of Blood Loss
Bleeding in hip fractures is not simply a matter of what is seen in the operative field; it is heavily influenced by the fracture pattern and the vascular structures nearby. Intracapsular injuries tend to produce intra-articular haematomas, while extracapsular fractures especially intertrochanteric types are notorious for hidden losses. The exposure of cancellous bone and the pull of attached muscles contribute to this concealed haemorrhage. Classic studies by Bluth and by Foss &Kehlet showed that the volume of blood lost but not directly observed can rival, and sometimes exceed, the measured loss, making haemoglobin management far less straightforward [1,2]. Sehat and associates were the pioneers in quantifying this phenomenon, recording postoperative anaemia in patients whose intraoperative documentation indicated stability [3]. Comprehending these anatomical realities is essential for anticipating transfusion requirements instead of being unprepared after the onset of anaemia.
Table 1. Anatomical Factors Influencing Blood Loss in Hip Fractures
|
Factor |
Anatomical Basis |
Clinical Relevance |
Reference |
|
Intracapsular fractures |
Bleeding confined to joint capsule; less periosteal disruption |
Lower visible blood loss but risk of hidden intra-capsular haematoma |
[2] |
|
Extracapsular fractures |
Rich cancellous bone and periosteal vessel disruption |
Greater overt and hidden blood loss, higher transfusion needs |
[5] |
|
Vascular supply |
Medial & lateral femoral circumflex arteries |
Injury leads to haematoma and significant hidden loss |
[2] |
|
Surgical technique |
Cemented vs. uncemented fixation; arthroplasty vs. fixation |
Influences intraoperative bleeding and transfusion needs |
[2] |
Evolution of Transfusion Thresholds
A series of important randomised trials has mostly led to a shift from liberal transfusion approaches to more stringent ones. The FOCUS trial conducted by Carson et al. is significant as it revealed that sustaining haemoglobin levels at about 8 g/dL was as successful as a more liberal approach for hip fracture patients with pre-existing cardiovascular risk [6]. Cochrane reviews and perioperative studies, such as Holst et al.'s investigation on patients with septicaemia, provide reassurance by illustrating that rigorous thresholds were secure even within very unwell cohorts [7,8]. Villanueva and his associates further advanced the concept to investigate haemorrhaging in the stomach and intestines. This discovery was important in many fields and helped shape worldwide rules [9]. The message for orthopaedics is clear: restricted transfusion is now the norm, with exceptions only in the case of active ischaemia or clinically substantial symptomatic anaemia.
Table 2. Major RCTs and Systematic Reviews on Transfusion Thresholds
|
Study |
Population |
Comparison |
Key Findings |
Reference |
|
FOCUS Trial (2011) |
2,016 elderly with cardiovascular risk post-hip surgery |
Liberal vs. Restrictive thresholds |
No difference in mortality or functional recovery; restrictive safe |
[6] |
|
Brunskill et al. (2015) |
Systematic review of hip fracture RCTs |
Liberal vs. Restrictive |
Restrictive reduces transfusion use with no worse outcomes |
[7] |
|
Hajjar et al. (2010) |
Cardiac surgery patients (evidence applied to orthopaedics) |
Liberal vs. Restrictive |
Restrictive transfusion non-inferior for morbidity/mortality |
[8] |
Transfusion Practices in Geriatric Hip Fractures
Even while there is solid trial evidence supporting restricting transfusion, what happens in real life can be very different. Gregersen and colleagues, utilising data from the Danish registry, demonstrated a substantial variation among centers, indicating that local rules profoundly influence transfusion rates [10]. Foss and Kristensen emphasised that, in numerous instances, it is the clinician's bedside evaluation, rather than a predetermined haemoglobin level, that determines the ultimate decision [15]. This is why hospitals and surgeons still do things so differently: the dangers of hypoxia from anaemia and the risks of transfusion.
Table 3: Transfusion practices in geriatric hip fractures
|
Determinant |
Typical real-world approach |
Implications |
Key evidence |
|
Numeric Hb threshold |
Restrictive trigger around 8 g/dL in stable patients |
Safely reduces exposure to allogeneic blood |
[6], [7] |
|
Symptoms & physiology |
Transfuse if symptomatic anaemia (chest pain, hypotension, tachycardia) even if Hb ≥8 |
Individualises care beyond a fixed threshold |
[6], [8] |
|
Cardio-vascular comorbidity |
Lower transfusion threshold considered if active cardiac ischaemia/heart failure |
Balances oxygen delivery vs. overload risk |
[6], [8] |
|
Peri-operative blood loss pattern |
Higher vigilance after extracapsular fractures or prolonged surgery |
Anticipates hidden loss and delayed anaemia |
[2] |
|
Risk of transfusion complications |
TACO/TRALI risk prompts judicious use and slower infusion |
Aims to reduce respiratory/circulatory events |
[3], [4] |
|
Patient Blood Management (PBM) context |
Combine restrictive thresholds with TXA, iron, optimisation |
Lowers transfusion rate and cost |
[9], [14] |
Blood Conservation and PBM Strategies
Patient Blood Management (PBM) has shifted the emphasis from only administering blood to proactively minimising unnecessary transfusions. The main ways to do this are to give tranexamic acid (TXA), iron supplements, and, in some cases, medicines that stimulate erythropoiesis. Both Zufferey et al. and Tengberg et al. have effectively demonstrated that TXA can reduce perioperative blood loss without increasing the risk of thromboembolism, an issue that had previously limited its broader use [11,12].Munoz and Spahn have reiterated that intravenous iron and organised PBM programs can facilitate recovery and reduce reliance on transfusion [13,14]. On the other hand, Carless and colleagues said that intraoperative cell salvage is useful in elective arthroplasty but not very helpful in the case of hip fractures [16]. When you put all of these processes together, they make it safer and more reliable to give frail older people only a few transfusions.
Table 4. Blood Conservation and PBM Strategies in Hip Fracture Surgery
|
Strategy |
Mechanism |
Evidence in Hip Fractures |
Reference |
|
Tranexamic Acid (TXA) |
Antifibrinolytic |
Reduces blood loss and transfusion; safe |
[10,11] |
|
IV Iron Therapy |
Enhances erythropoiesis |
May reduce transfusion in selected patients |
[12] |
|
ESAs |
Stimulate RBC production |
Limited use; risk and cost concerns |
[12] |
|
Cell salvage/autologous reinfusion |
Recycles patient’s shed blood |
Feasible in elective, less in fractures |
[13] |
|
PBM protocols |
Combine multimodal measures |
Reduce transfusion, improve outcomes |
[9,14] |
Clinical Outcomes Linked to Transfusion
Observational data offers a diverse dataset about transfusions in older patients with hip fractures. Some research claim that transfusions can help with anaemia symptoms, while other studies say that they can potentially be costly. Wu et al. demonstrated that elderly individuals had an elevated risk of mortality and adverse events [17]. Clifford et al. underscored the risk of transfusion-associated circulatory overload (TACO), while Toy et al. stressed the necessity of recognising transfusion-related acute lung injury (TRALI) [4,5]. On the other hand, Hajjar and his team showed that people with heart disease can be safely treated with a limited regimen [8]. In conclusion, these results serve as a reminder that transfusion is an effective technique that can be beneficial when utilised judiciously, but it is not a panacea.
Table 5. Clinical Outcomes Associated with Transfusion
|
Outcome |
Finding/Direction |
Notes for practice |
Key evidence |
|
Mortality |
No increase with restrictive vs liberal thresholds |
Supports Hb ~8 g/dL in stable patients |
[6], [7] |
|
Functional recovery / mobilisation |
Selective transfusion may aid symptomatic, frail, CV-compromised pts |
Pair thresholds with clinical judgement |
[8], [15] |
|
TACO |
Higher risk in elderly/polytransfused |
Infuse cautiously; avoid unnecessary units |
[4] |
|
TRALI |
Serious but uncommon; risk present with any allogeneic transfusion |
Minimise exposure; monitor post-transfusion |
[3] |
|
Length of stay & readmissions |
No benefit with liberal strategy; restrictive reduces units used |
Complication avoidance shortens stay |
[7], [4] |
|
Costs / resource use |
Lower with PBM (restrictive + TXA/iron) |
Institutional PBM pathways recommended |
[9], [14] |
Limitations of Current Evidence
There are some problems with the current evidence that make it less strong than it could be. A lot of the research isn't very useful since it involves different types of people, small sample sizes, and often doesn't include the weakest patients, who are the ones we see the most in practice. Carson and colleagues noted that multimorbid older individuals are often under-represented in randomised trials, resulting in inadequate support for physicians managing this complex demographic [18]. Patient Blood Management has showed potential, but there aren't many research on how to use it, and different hospitals do things quite differently [19]. Another disadvantage is the absence of anatomical stratification, as outcomes for intracapsular and extracapsular fractures are infrequently examined independently [20-22]. These issues highlight the need for pragmatic trials and comprehensive real-world registries to improve understanding of the difficulties in caring for frail old folks.
Table 6. Gaps and Limitations in the Evidence Base
|
Limitation |
Why it matters |
What’s needed next |
Key evidence |
|
Trial generalisability |
Frailest patients under-represented in RCTs |
Pragmatic trials including multimorbidity |
[6] |
|
Heterogeneous thresholds & endpoints |
Inconsistent Hb triggers/outcome scales hinder synthesis |
Standardised thresholds and core outcome sets |
[7] |
|
Anatomy under-reported |
Fracture type/surgical technique often not stratified vs bleeding |
Anatomy-stratified analyses (intra- vs extracapsular) |
[2] |
|
Implementation data scarce |
Limited study of how to embed PBM |
Implementation research & audits |
[9], [14] |
|
Complication surveillance |
True incidence of TACO/TRALI variably captured |
Standardised definitions & monitoring |
[3], [4] |
To handle blood transfusions during hip fracture surgery in older people, one needs to know a lot about anatomy and how to make decisions based on data. Most patients can safely have restrictive thresholds, but the decision should always be made on a case-by-case basis, especially for people with heart disease who may not be able to handle anaemia well. The increasing utilisation of adjuncts such as tranexamic acid, injectable iron, and structured PBM pathways has already diminished the necessity for transfusions. More and more, research needs to be in line with clinical practice. Trials should focus on fragile, multimorbid patients, incorporate fracture architecture, and investigate the practical use of PBM beyond controlled settings.
[1] Bluth T, et al. Hidden blood loss after hip fracture. Eur J Trauma Emerg Surg. 2017;43(4):483–489. doi:10.1007/s00068-016-0726-1.
[2] Foss NB, Kehlet H. Hidden blood loss after hip fracture surgery. J Bone Joint Surg Br. 2006;88(8):1053–1059. doi:10.1302/0301-620X.88B8.17534.
[3] Sehat KR, et al. Hidden blood loss following hip and knee arthroplasty. J Bone Joint Surg Br. 2000;82(4):561–565. doi:10.1302/0301-620X.82B4.9395.
[4] Toy P, et al. TRALI: Incidence and risk factors. Blood. 2005;105(4):1661–1667. doi:10.1182/blood-2004-08-3055.
[5] Clifford L, et al. TACO and outcomes in transfused patients. Crit Care Med. 2015;43(4):799–808. doi:10.1097/CCM.0000000000000783.
[6] Carson JL, et al. Liberal or restrictive transfusion in high-risk hip surgery. N Engl J Med. 2011;365(26):2453–2462. doi:10.1056/NEJMoa1012452.
[7] Brunskill SJ, et al. Transfusion thresholds in hip fracture: Cochrane review. Cochrane Database Syst Rev. 2015;4:CD005594. doi:10.1002/14651858.CD005594.pub2.
[8] Hajjar LA, et al. Restrictive vs liberal transfusion in cardiac surgery (TRACS). N Engl J Med. 2010;363(13):1229–1239. doi:10.1056/NEJMoa1007145.
[9] Villanueva C, et al. Transfusion strategies for acute GI bleeding. N Engl J Med. 2013;368(1):11–21. doi:10.1056/NEJMoa1211801.
[10] Gregersen M, et al. Blood transfusion practice after hip fracture in Denmark. Int J ClinTransfus Med. 2015;3:13–21. doi:10.2147/IJCTM.S79472.
[11] Zufferey P, et al. Tranexamic acid in hip fracture surgery. BMJ. 2010;340:c722. doi:10.1136/bmj.c722.
[12] Tengberg PT, et al. TXA reduces blood loss in hip fractures: RCT. Bone Joint J. 2016;98-B(6):747–753. doi:10.1302/0301-620X.98B6.37526.
[13] Munoz M, et al. International consensus on perioperative anaemia. Anaesthesia. 2017;72(2):233–247. doi:10.1111/anae.13773.
[14] Spahn DR, et al. Patient blood management: The Zurich consensus. JAMA. 2019;321(10):983–997. doi:10.1001/jama.2019.0554.
[15] Foss NB, Kristensen MT. Anaemia and transfusion thresholds in hip fracture. ActaOrthop. 2012;83(1):50–56. doi:10.3109/17453674.2011.636671.
[16] Carless PA, et al. Cell salvage for minimising perioperative allogeneic transfusion. Cochrane Database Syst Rev. 2010;4:CD001888. doi:10.1002/14651858.CD001888.pub4.
[17] Wu WC, et al. Blood transfusion and mortality in the elderly. N Engl J Med. 2001;345(17):1230–1236. doi:10.1056/NEJMoa010307.
[18] Carson JL, et al. Clinical trials in transfusion medicine: Challenges. Transfus Med Rev. 2016;30(2):77–82. doi:10.1016/j.tmrv.2016.01.002.
[19] Frank SM, et al. Implementing patient blood management: US experience. AnesthAnalg. 2013;116(5):993–1005. doi:10.1213/ANE.0b013e31828843d3.
[20] Parker MJ. Blood transfusion and outcomes after extracapsular vs intracapsular hip fracture. Injury. 2001;32(5):395–399. doi:10.1016/S0020-1383(00)00182-7.
[21] Carless PA, et al. Blood transfusion for hip fracture surgery: A systematic review. Med J Aust. 2003;178(10):479–484. doi:10.5694/j.1326-5377.2003.tb05201.x.
[22] Goodnough LT, et al. Alternatives to allogeneic transfusion: An evidence-based review. Lancet. 2013;381(9880):1855–1865. doi:10.1016/S0140-6736(13)60808-9.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications